Patent intelligence · CA
CA 3147876
DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER
DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER
Patent details — CA 3147876
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Feb 4, 2021
- Expiration
- Jan 30, 2041
- Applicant
- BASILEA PHARM INT AG [CH]
- CPC classes
- A61K 31/ 444 A I, A61K 31/ 497 A I, A61K 31/ 498 A I, A61K 31/ 4439 A I
Quick answer
CA 3147876 (DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Feb 4, 2021. Expires Jan 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BASILEA PHARM INT AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 444 A I, A61K 31/ 497 A I, A61K 31/ 498 A I, A61K 31/ 4439 A I, A61K 31/ 4545 A I, A61K/314439
More from BASILEA PHARM INT AG [CH]
Related pharmaceutical patents in our USPTO index.
-
AU 2024384453
CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
PT 3886798
COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
US 20260042800
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
WO 2025114603
COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES
granted -
WO 2024094329
PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM
granted -
CA 3268414
MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS
granted -
AU 2022323463
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
AR 127448
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
granted
Frequently asked questions
What is US patent 3147876?
CA 3147876 (DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Feb 4, 2021. Expires Jan 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3147876?
BASILEA PHARM INT AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3147876 expire?
Our index shows an expiration date of Jan 30, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.